Tegavivint + Pembrolizumab for Liver Cancer

Phase 1 & 2

Recruiting

Research Sponsored by Iterion Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up tumors will be assessed at baseline and every 8 weeks until end of treatment, an average of 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial will test a new drug to treat advanced liver cancer after other treatments have failed. It will also study the drug combined with another medicine.

Who is the study for?

Adults with advanced liver cancer (HCC) who've had at least one prior systemic therapy can join. They must have measurable disease, certain blood and organ function levels, controlled hepatitis B or cured hepatitis C, and no severe heart issues. Pregnant women and those with other active cancers or recent major surgeries cannot participate.

What is being tested?

The trial has two parts: first testing Tegavivint alone in different doses for HCC patients after other treatments failed; second combining Tegavivint with Pembrolizumab to find the best dose. Participants are chosen based on specific genetic markers in their tumors.

What are the potential side effects?

Possible side effects include immune system reactions, fatigue, digestive problems, skin changes, potential heart rhythm issues due to Tegavivint's effect on cells' signaling pathways. Pembrolizumab may cause similar immune-related side effects.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ tumors will be assessed at baseline and every 8 weeks until end of treatment, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~tumors will be assessed at baseline and every 8 weeks until end of treatment, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and tumors will be assessed at baseline and every 8 weeks until end of treatment, an average of 1 year for reporting.